GMP – Page 73 – Pharma.Tips

Equipment downtime due to cleaning during CPV review – cycle time reduction with compliance assurance

Minimizing Equipment Downtime During CPV Reviews: Strategies for Compliance and Cycle Time Reduction Equipment downtime due to cleaning processes can significantly impact operational efficiency, particularly during a Critical Process Validation…

Inadequate GMP training during internal audit – FDA/EMA inspection citation risk

Managing the Risks of Inadequate GMP Training in Internal Audits In pharmaceutical manufacturing, the robustness of your Good Manufacturing Practices (GMP) training program can significantly impact compliance and overall quality…

Poor change control discipline during scale-up – evidence package for inspection defense

Effective Strategies to Address Poor Change Control during Scale-Up In the pharmaceutical manufacturing arena, the process of scaling up is pivotal yet fraught with the potential for oversight, particularly with…

Repeated GMP deviations during technology transfer – evidence package for inspection defense

Defending Against Repeated GMP Deviations During Technology Transfer Repeated GMP deviations during technology transfer present a significant risk to pharmaceutical companies, compromising product quality, regulatory compliance, and operational efficiency. These…

Inefficient CIP cycle during CPV review – cycle time reduction with compliance assurance

Addressing Inefficient CIP Cycles During CPV Review for Enhanced Compliance The pharmaceutical industry often faces challenges related to inefficient Clean-in-Place (CIP) cycles, particularly during Continuous Process Verification (CPV) reviews. Inefficient…

Uncontrolled SOP changes during scale-up – CAPA framework to prevent recurrence

Managing Uncontrolled SOP Changes During Scale-Up: A CAPA Framework Operational challenges often arise during the scale-up of pharmaceutical manufacturing processes. One major concern is the occurrence of uncontrolled changes in…

Inconsistent GMP interpretation during internal audit – how to rebuild GMP maturity

Addressing Inconsistent GMP Interpretation during Internal Audits to Elevate GMP Maturity Inconsistent interpretations of Good Manufacturing Practices (GMP) during internal audits represent a critical challenge for pharmaceutical manufacturers aiming for…

Inconsistent GMP interpretation during regulatory inspection – evidence package for inspection defense

“`html Addressing Inconsistent GMP Interpretation During Regulatory Inspections: An Actionable Playbook Inconsistent interpretations of Good Manufacturing Practices (GMP) during regulatory inspections can lead to significant challenges for pharmaceutical manufacturers. Oftentimes,…

Tag: GMP

Equipment downtime due to cleaning during CPV review – cycle time reduction with compliance assurance

Inadequate GMP training during internal audit – FDA/EMA inspection citation risk

Poor change control discipline during scale-up – evidence package for inspection defense

Repeated GMP deviations during technology transfer – evidence package for inspection defense

Inefficient CIP cycle during CPV review – cycle time reduction with compliance assurance

Uncontrolled SOP changes during scale-up – CAPA framework to prevent recurrence

Inconsistent GMP interpretation during internal audit – how to rebuild GMP maturity

Inconsistent GMP interpretation during regulatory inspection – evidence package for inspection defense

Redundant cleaning steps during multi-product campaigns – cycle time reduction with compliance assurance

Weak management oversight during technology transfer – evidence package for inspection defense

Batch documentation gaps during routine manufacturing – CAPA framework to prevent recurrence

Batch documentation gaps during technology transfer – CAPA framework to prevent recurrence